Treatment at scale in Brazil: A physician's perspective

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Schechter, Mauro ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

AIDS; Antiretroviral therapy; Brazil; HIV; Operational research

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAZIL; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COMORBIDITY; COST OF ILLNESS; DEVELOPING COUNTRY; DRUG EFFICACY; HEALTH CARE FACILITY; HEALTH PROGRAM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LABORATORY TEST; LIFE EXPECTANCY; LONG TERM CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; BRAZIL; CAUSE OF DEATH; COMORBIDITY; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 34447327543     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279704.16804.ae     Document Type: Review

References (39)

1. Beyrer C, Gauri V, Vaillancourt D. Evaluation of the World Bank Assistance in responding to the AIDS epidemic: Brazil Case Study. Washington, DC: World Bank; 2005. Available at: http://www.worldbank.org/oed/ aids. Accessed: 18 January 2007.
2. Schechter M, Kallas EG. HIV/AIDS research in Brazil: the missing piece? Future Virol 2006; 1:409-413.
3. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546.
4. Fonseca LA, Reingold AL, Casseb JR, Brigido LF, Duarte AJ. AIDS incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in Sao Paulo, Brazil. Int J Epidemiol 1999; 28:1156-1160.
5. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-1682.
6. Matida LH, Marcopito LF, Succi RC, Marques HH, Della Negra M, Grangeiro A, Hearst N. Improving survival among Brazilian children with perinatally-acquired AIDS. Braz J Infect Dis 2004; 8:419-423.
7. Santoro-Lopes G, Harrison LH, Moulton LH, Lima LA, de Pinho AM, Hofer C, Schechter M. Gender and survival after AIDS in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:403-407.
8. Teixeira PR, Vitoria MA, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 2004; 18 (Suppl. 3):S5-S7.
9. Levi GC, Vitoria MA. Fighting against AIDS: the Brazilian experience. AIDS 2002; 16:2373-2383.
10. Diaz RS, Kallas EG, Castelo A, Rawal BD, Busch MP. Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing. AIDS 1999; 13:1417-1418.
11. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519-525.
12. Barreto CC, Sabino EC, Goncalez TT, Laycock ME, Pappalardo BL, Salles NA, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in Sao Paulo, Brazil. Transfusion 2005; 45:1709-1714.
13. Teixeira SL, Bastos FI, Telles PR, Hacker MA, Brigido LF, de FOCA, et al. HIV-1 infection among injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incidence and genetic diversity. J Clin Virol 2004; 31:221-226.
14. De Freitas Oliveira CA, Ueda M, Yamashiro R, Rodrigues R, Sheppard HW, de Macedo Brigido LF. Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002. J Clin Microbiol 2005; 43:1439-1442.
15. World Bank. Brazil country brief. Washington, DC; 2006. Available at: http://web.worldbank.org. Accessed: 18 January 2007.
16. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
17. Recommendations for antiretroviral therapy for HIV-infected adolescents and adults, 2006. Brazil Ministry of Health, National AIDS Programme. AIDS; 2006. Available at: http://www.aids.gov.br. Accessed: 18 January 2007.
18. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva; 2006. Available at: http://www.who.int/hiv/pub/guidelines/adult/en/ index.html. Accessed: 18 January 2007.
19. Melchior R, Nemes MI, Basso CR, Castanheira ER, Alves MT, Buchalla CM, Donini AA. Evaluation of the organizational structure of HIV/AIDS outpatient care in Brazil. Rev Saude Publica 2006; 40:143-151.
20. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
21. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
22. Anastos K, Barron Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, et al. The prognostic importance of changes in CD4R cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-264.
23. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005; 40:324-328.
24. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
25. Synovate Healthcare. HIV in Brazil Monitor. Phase 2006 Q3.
26. Medecins Sans Frontieres. Antiretroviral treatment projects worldwide. GMHC Treat Issues 2003; 17:7. Available at http://www.gmhc.org/health/treatment/ti/ti1707.html#3.
27. Copackaged drug regimen approved for PEPFAR. AIDS Alert 2005; 20(4):46.
28. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
29. Medeiros R, Diaz RS, Filho AC. Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis 2002; 6:298-304.
30. Schechter M, Zajdenverg R, Machado LL, Pinto ME, Lima LA, Perez MA. Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system. J Acquir Immune Defic Syndr 1994; 7:163-168.
31. Soares EC, Saraceni V, Lauria L, de M, Pacheco AG, Durovni B, Cavalcante SC. Tuberculosis as a disease defining acquired immunodeficiency syndrome: ten years of surveillance in Rio de Janeiro, Brazil. J Bras Pneumol 2006; 32:444-448.
32. De Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15:2129-2135.
33. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4:1026-1031.
34. Golub J, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: in press.
35. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454.
36. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
37. Pereira CC, Machado CJ, Rodrigues Rdo N. Profiles of multiple causes of death related to HIV/AIDS in the cities of Sao Paulo and Santos, Brazil [in Portuguese]. Cad Saude Publica 2007; 23:645-655.
38. Santo AH. Deaths attributed to multiple causes and involving tuberculosis in the state of Rio de Janeiro Brazil between 1999 and 2001. J Bras Pneumol 2006; 32:544-552.
39. Martinez E, Milinkovic A, Buira E, de Lazzari E, Leon A, Larrousse M, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 2007; 8:251-258.